David Kirn - 21 Feb 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Executive Officer, Director
Signature
/s/ August J. Moretti, Attorney-in-Fact for David Kirn
Issuer symbol
FDMT
Transactions as of
21 Feb 2023
Transactions value $
-$709,873
Form type
4
Filing time
23 Feb 2023, 18:56:02 UTC
Previous filing
14 Feb 2023
Next filing
04 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Sale -$358K -17.1K -0.9% $20.93 1.88M 21 Feb 2023 Direct F1, F2
transaction FDMT Common Stock Sale -$19.5K -907 -0.05% $21.49 1.88M 21 Feb 2023 Direct F1, F3
transaction FDMT Common Stock Sale -$333K -16.4K -0.88% $20.22 1.86M 22 Feb 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $20.35 to $21.305, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $21.40 to $21.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The transaction was executed in multiple trades in prices ranging from $19.96 to $20.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.